Big data may be prolonging development times for new pharmaceuticals, as companies struggle to cope with diverse digital applications and clinical trial protocol changes.

Urgent calls for industry to generate and apply real world evidence were matched at a recent conference only by complaints about challenges faced by this growing, ill-defined evidence category.

By adding another AI deal to Sanofi's innovation quiver, the French group says it's widening its hunt to find single molecules that offer dual or multi-specific targeting to fight disease.